Loading quotes...
Forecast
The analysts' average price target is €12.86 (+18,867.55%). The median is €12.74 (+18,690.56%).
| Buy |
Â
6 |
| Hold |
Â
3 |
| Sell |
Â
0 |
News Go to news feed
Zynex files for Chapter 11 — shares plunge about 55%
Medical technology company Zynex has voluntarily filed for bankruptcy and submitted a Chapter 11 petition, after which the stock fell 55.2%. Zynex initiated a court‑supervised financial restructuring supported by creditors who are expected to provide new financing. According to the company, operations will continue without interruption for patients, customers and employees. Zynex did not disclose the exact reasons for the filing or the terms of the new financing. » More on de.investing.com
Zynex misses Q3 2025 forecasts badly, stock falls more than 20%
Zynex reported a loss of $1.42 per share for Q3 2025 on revenue of $13.36 million, missing analysts’ expectations by a wide margin. Operational disruptions, including the suspension of TRICARE payments and changed submission processes, led to steep year‑over‑year revenue declines. After the results, the stock fell about 20.6% to $0.48; management installed new leadership, engaged Province LLC to explore strategic alternatives, and has begun talks with bondholders on financing and restructuring, while $60 million of convertible notes mature in May 2026. » More on de.investing.com
Zynex considers strategic options after share price plunge
Zynex's stock fell about 26.7% after the company announced it had engaged Province LLC as a financial adviser to review strategic alternatives such as capital raising and restructuring measures. Zynex formed a special committee of independent directors, led by Paul Aronzon, to oversee the evaluation of options. No specific deal has been identified and there is no guarantee the review will lead to a transaction, which appears to have worried investors. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2025 | YoY |
|---|---|---|
| Revenue | 11.38M | - |
| Gross profit | 6.88M | - |
| Net profit | -36.57M | - |
| EBITDA | -36.59M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.4M |
Number of shares | 30.39M |
52-week high/low | €7.56 - €0.0279 |
| Dividends | No |
Beta | 1.00 |
P/E ratio | -0.03 |
PEG ratio | 0.00 |
P/B ratio | -0.04 |
P/S ratio | 0.05 |
Company profile
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
| Name | ZYNEX INC. DL-,001 |
| CEO | Steven Lewis Dyson |
| Headquarters | Englewood,
co USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 02/25/2004 |
| Employees | 1,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ZYXI |